Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel Free HYPR Stock Alerts

Hyperfine (HYPR) Competitors

Hyperfine logo
$0.93 -0.01 (-1.00%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$0.93 +0.00 (+0.35%)
As of 10/9/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

HYPR vs. OBIO, CV, MOBI, TMCI, and TLSI

Should you buy Hyperfine stock or one of its competitors? Hyperfine's main competitors and comparable companies include Orchestra BioMed (OBIO), CapsoVision (CV), Mobia Medical (MOBI), Treace Medical Concepts (TMCI), and TriSalus Life Sciences (TLSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Hyperfine compare to Orchestra BioMed?

Orchestra BioMed (NASDAQ:OBIO) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Hyperfine has lower revenue, but higher earnings than Orchestra BioMed. Orchestra BioMed is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Orchestra BioMed$33.48M10.68-$52.70M-$0.85N/A
Hyperfine$16.54M5.97-$35.57M-$0.38N/A

Orchestra BioMed has a net margin of -184.60% compared to Hyperfine's net margin of -210.75%. Hyperfine's return on equity of -97.88% beat Orchestra BioMed's return on equity.

Company Net Margins Return on Equity Return on Assets
Orchestra BioMed-184.60% -149.61% -54.15%
Hyperfine -210.75%-97.88%-61.81%

Orchestra BioMed has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.45, indicating that its share price is 45% more volatile than the broader market.

53.2% of Orchestra BioMed shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 7.5% of Orchestra BioMed shares are held by insiders. Comparatively, 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Orchestra BioMed presently has a consensus target price of $13.17, indicating a potential upside of 121.29%. Hyperfine has a consensus target price of $2.03, indicating a potential upside of 118.47%. Given Orchestra BioMed's stronger consensus rating and higher possible upside, research analysts plainly believe Orchestra BioMed is more favorable than Hyperfine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orchestra BioMed
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
Hyperfine
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Hyperfine had 1 more articles in the media than Orchestra BioMed. MarketBeat recorded 9 mentions for Hyperfine and 8 mentions for Orchestra BioMed. Orchestra BioMed's average media sentiment score of 0.44 beat Hyperfine's score of 0.40 indicating that Orchestra BioMed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Orchestra BioMed
2 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hyperfine
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Orchestra BioMed beats Hyperfine on 9 of the 16 factors compared between the two stocks.

How does Hyperfine compare to CapsoVision?

CapsoVision (NASDAQ:CV) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

CapsoVision has a beta of -2.45, suggesting that its stock price is 345% less volatile than the broader market. Comparatively, Hyperfine has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

CapsoVision has higher earnings, but lower revenue than Hyperfine. CapsoVision is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CapsoVision$13.55M24.34-$25.32M-$0.47N/A
Hyperfine$16.54M5.97-$35.57M-$0.38N/A

In the previous week, Hyperfine had 6 more articles in the media than CapsoVision. MarketBeat recorded 9 mentions for Hyperfine and 3 mentions for CapsoVision. Hyperfine's average media sentiment score of 0.40 beat CapsoVision's score of -0.36 indicating that Hyperfine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CapsoVision
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hyperfine
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CapsoVision currently has a consensus target price of $9.50, suggesting a potential upside of 44.16%. Hyperfine has a consensus target price of $2.03, suggesting a potential upside of 118.47%. Given Hyperfine's stronger consensus rating and higher probable upside, analysts clearly believe Hyperfine is more favorable than CapsoVision.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CapsoVision
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Hyperfine
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Hyperfine has a net margin of -210.75% compared to CapsoVision's net margin of -214.74%. Hyperfine's return on equity of -97.88% beat CapsoVision's return on equity.

Company Net Margins Return on Equity Return on Assets
CapsoVision-214.74% -177.85% -135.07%
Hyperfine -210.75%-97.88%-61.81%

15.0% of Hyperfine shares are owned by institutional investors. 2.3% of CapsoVision shares are owned by company insiders. Comparatively, 26.3% of Hyperfine shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Hyperfine beats CapsoVision on 14 of the 16 factors compared between the two stocks.

How does Hyperfine compare to Mobia Medical?

Mobia Medical (NASDAQ:MOBI) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

Hyperfine has lower revenue, but higher earnings than Mobia Medical. Hyperfine is trading at a lower price-to-earnings ratio than Mobia Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mobia Medical$32.04M8.97-$46.50M-$20.18N/A
Hyperfine$16.54M5.97-$35.57M-$0.38N/A

Mobia Medical has a net margin of 0.00% compared to Hyperfine's net margin of -210.75%. Mobia Medical's return on equity of 0.00% beat Hyperfine's return on equity.

Company Net Margins Return on Equity Return on Assets
Mobia MedicalN/A N/A N/A
Hyperfine -210.75%-97.88%-61.81%

In the previous week, Hyperfine had 4 more articles in the media than Mobia Medical. MarketBeat recorded 9 mentions for Hyperfine and 5 mentions for Mobia Medical. Hyperfine's average media sentiment score of 0.40 beat Mobia Medical's score of 0.34 indicating that Hyperfine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mobia Medical
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Hyperfine
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

15.0% of Hyperfine shares are held by institutional investors. 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Mobia Medical currently has a consensus target price of $20.75, suggesting a potential upside of 140.44%. Hyperfine has a consensus target price of $2.03, suggesting a potential upside of 118.47%. Given Mobia Medical's stronger consensus rating and higher possible upside, analysts plainly believe Mobia Medical is more favorable than Hyperfine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mobia Medical
1 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.57
Hyperfine
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Summary

Mobia Medical beats Hyperfine on 9 of the 15 factors compared between the two stocks.

How does Hyperfine compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and Hyperfine (NASDAQ:HYPR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Hyperfine has lower revenue, but higher earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Treace Medical Concepts$212.69M1.21-$59M-$0.93N/A
Hyperfine$16.54M5.97-$35.57M-$0.38N/A

Treace Medical Concepts has a beta of 1.48, suggesting that its share price is 48% more volatile than the broader market. Comparatively, Hyperfine has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market.

84.1% of Treace Medical Concepts shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by insiders. Comparatively, 26.3% of Hyperfine shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Hyperfine had 8 more articles in the media than Treace Medical Concepts. MarketBeat recorded 9 mentions for Hyperfine and 1 mentions for Treace Medical Concepts. Hyperfine's average media sentiment score of 0.40 beat Treace Medical Concepts' score of 0.00 indicating that Hyperfine is being referred to more favorably in the news media.

Company Overall Sentiment
Treace Medical Concepts Neutral
Hyperfine Neutral

Treace Medical Concepts currently has a consensus target price of $5.17, indicating a potential upside of 30.89%. Hyperfine has a consensus target price of $2.03, indicating a potential upside of 118.47%. Given Hyperfine's stronger consensus rating and higher probable upside, analysts plainly believe Hyperfine is more favorable than Treace Medical Concepts.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Treace Medical Concepts
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.86
Hyperfine
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Treace Medical Concepts has a net margin of -28.99% compared to Hyperfine's net margin of -210.75%. Treace Medical Concepts' return on equity of -71.37% beat Hyperfine's return on equity.

Company Net Margins Return on Equity Return on Assets
Treace Medical Concepts-28.99% -71.37% -30.49%
Hyperfine -210.75%-97.88%-61.81%

Summary

Hyperfine beats Treace Medical Concepts on 10 of the 16 factors compared between the two stocks.

How does Hyperfine compare to TriSalus Life Sciences?

Hyperfine (NASDAQ:HYPR) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

Hyperfine presently has a consensus price target of $2.03, indicating a potential upside of 118.47%. TriSalus Life Sciences has a consensus price target of $10.20, indicating a potential upside of 151.23%. Given TriSalus Life Sciences' higher possible upside, analysts plainly believe TriSalus Life Sciences is more favorable than Hyperfine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hyperfine
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
TriSalus Life Sciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by company insiders. Comparatively, 16.3% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TriSalus Life Sciences has a net margin of -62.59% compared to Hyperfine's net margin of -210.75%. TriSalus Life Sciences' return on equity of 0.00% beat Hyperfine's return on equity.

Company Net Margins Return on Equity Return on Assets
Hyperfine-210.75% -97.88% -61.81%
TriSalus Life Sciences -62.59%N/A -64.47%

Hyperfine has a beta of 1.45, suggesting that its share price is 45% more volatile than the broader market. Comparatively, TriSalus Life Sciences has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Hyperfine has higher earnings, but lower revenue than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Hyperfine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hyperfine$16.54M5.97-$35.57M-$0.38N/A
TriSalus Life Sciences$45.08M5.55-$39.23M-$1.30N/A

In the previous week, Hyperfine had 3 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 9 mentions for Hyperfine and 6 mentions for TriSalus Life Sciences. Hyperfine's average media sentiment score of 0.40 beat TriSalus Life Sciences' score of -0.13 indicating that Hyperfine is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hyperfine
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
TriSalus Life Sciences
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Hyperfine beats TriSalus Life Sciences on 10 of the 14 factors compared between the two stocks.

Get Hyperfine News Delivered to You Automatically

Sign up to receive the latest news and ratings for HYPR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HYPR vs. The Competition

Export
MetricHyperfineHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$98.70M$5.43B$7.16B$13.21B
Dividend YieldN/A1.77%2.53%16.37%
P/E RatioN/A25.57275.3026.16
Price / Sales8.6683.34635.99108.09
Price / CashN/A31.8776.3853.09
Price / Book2.225.9511.226.33
Net Income-$35.57M$146.18M$3.50B$382.15M
7 Day Performance4.13%-0.28%-0.89%-1.40%
1 Month Performance18.35%-1.88%-4.42%-3.47%
1 Year Performance-46.82%5.45%7.03%1.18%

Hyperfine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HYPR
Hyperfine
2.854 of 5 stars		$0.93
-1.0%		$2.03
+118.5%		-53.0%$98.70M$11.40MN/A102
OBIO
Orchestra BioMed
3.6039 of 5 stars		$6.08
+3.2%		$13.17
+116.6%		+107.3%$354.02M$33.48MN/A4
CV
CapsoVision
3.5027 of 5 stars		$6.69
-3.3%		$9.50
+42.0%		+42.0%$346.33M$13.55MN/A99
MOBI
Mobia Medical
3.7334 of 5 stars		$9.02
+2.2%		$20.75
+130.0%		N/A$293.96M$32.04MN/A167
TMCI
Treace Medical Concepts
3.0908 of 5 stars		$4.62
+3.1%		$5.17
+11.9%		-34.5%$291.36M$212.69MN/A450

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:HYPR) was last updated on 10/10/2026 by MarketBeat.com Staff.
From Our Partners
New Chip takes minutes, not days
George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...
Eagle Publishing | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
This high yielding “gold annuity” is starting to move…
Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...
Golden Portfolio | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Trump goes "all-in" on Grand Canyon energy breakthrough
A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...
Behind the Markets | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel